secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2024-05-28T23:59:59+00:00
Accession:  0001628280-24-025418
Event type: other
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion shareholders approve 6.25M share increase to 2022 stock plan and 6.175M increase to ESPP
--------------------------------------------------------------------------------

- Stockholders re-elected directors Antonio M. Gotto Jr. and Nicole Vitullo with 87.9M and 91.0M votes for, respectively.
- Advisory say-on-pay proposal approved with 70.7M votes (74% of votes cast).
- Ratification of Ernst & Young as auditor for FY2024 approved with 136.8M votes (98.3% of votes cast).
- Amendment to 2022 Stock Option Plan increasing authorized shares by 6,250,000 approved with 88.1M votes.
- Amendment to 2020 ESPP increasing reserved shares by 6,175,000 approved with 88.8M votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024025418/0001628280-24-025418-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828024025418/espr-20240523.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-025418

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer